Long-term follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-risk Neuroblastoma: Children’s Oncology Group Study ANBL0032

PURPOSE: Previously our randomized Phase III trial demonstrated that immunotherapy including dinutuximab, a chimeric anti-GD2 monoclonal antibody, granulocyte macrophage-colony stimulating factor (GM-CSF), and interleukin-2 (IL2) improved survival for children with high-risk neuroblastoma that had r...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Clin Cancer Res
Hlavní autoři: Yu, Alice L., Gilman, Andrew L., Ozkaynak, M. Fevzi, Naranjo, Arlene, Diccianni, Mitchell B., Gan, Jacek, Hank, Jacquelyn A., Batova, Ayse, London, Wendy B., Tenney, Sheena C., Smith, Malcolm, Shulkin, Barry L., Parisi, Marguerite, Matthay, Katherine K., Cohn, Susan L., Maris, John M., Bagatell, Rochelle, Park, Julie R., Sondel, Paul M.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2021
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8046731/
https://ncbi.nlm.nih.gov/pubmed/33504555
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-20-3909
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky